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Abstract
 .Nonsteroidal anti-inflammatory drugs NSAIDs and short-chain fatty acids are effective suppressors of colorectal cancer
 .that may work in part by accentuating apoptosis of transformed cells. Since reactive oxygen species ROS can play an
important role in regulating cell growth and cell death, we determined the effect of the NSAIDs indomethacin and salicylic
acid, and the short-chain fatty acids butyrate and propionate on ROS metabolism in the HT-29 human colorectal carcinoma
cell line. We find that all of these agents increase cellular peroxide generation, as determined by two independent assays.
Arachidonic acid was also found to increase ROS generation, and could synergize with indomethacin in this reaction. The
NSAIDs and short-chain fatty acids under study all possess a carboxyl group, and this carboxyl group is essential for
salicylic acid’s ability to increase ROS production. Although the two NSAIDs examined increase peroxide production, they
 .were both found to suppress superoxide generation by vitamin K3 menadione , a redox cycling compound similar to those
found in the colon. The short-chain fatty acids did not have this activity. The ability of these NSAIDs and short-chain fatty
acids to alter cellular ROS metabolism may contribute to their chemopreventive activity. q 1998 Elsevier Science B.V.
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1. Introduction
Colon cancer is the second leading cause of death
due to cancer in both men and women in the western
w xworld 1 . Chemopreventive agents, such as nons-
 .teroidal anti-inflammatory drugs NSAIDs and
short-chain fatty acids derived from dietary fiber,
have however been shown to substantially reduce the
w xrisk of colon cancer 2–4 . The mechanism by which
these chemopreventive agents function is not com-
pletely understood. A better understanding of how
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these agents work could lead to the development of
more effective cancer-preventing dietary regiments
and supplements.
The effectiveness of the NSAID acetylsalicylic
 .acid aspirin as an anti-cancer agent was revealed
through epidemiological studies: a 50% reduction in
the incidence of colorectal cancer has been noted for
w xregular users of aspirin 2,5 . Another NSAID, sulin-
dac, causes regression of colorectal polyps in patients
w xwith familial adenomatous polyposis 6 . The protec-
tive effects of aspirin, sulindac and other NSAIDs
have also been observed in animal models, reducing
the formation of chemically induced and spontaneous
w xtumors 3 . The mechanism by which NSAIDs sup-
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press the development of colon cancer may be multi-
faceted. Evidence has been obtained indicating that
these drugs can reduce the activation of pro-carcino-
w xgens 3 , and may even increase carcinogen detoxifi-
cation by increasing the levels of glutathione S-trans-
w xferase in the gut 7 . NSAIDs also appear to increase
apoptosis of cancer cells: sulindac was found to
approximately triple the number of apoptotic cells in
the colonic epithelium of patients with familial ade-
w xnomatous polyposis 8 . The ability of NSAIDs to
induce apoptosis in cancer cells has also been found
w x w xto occur in vitro 9–11 . Elder et al. 9 , for example,
 .demonstrated that salicylic acid SA selectively in-
duces apoptosis in a number of colorectal carcinoma
cell lines.
The precise biochemical mechanism by which
NSAIDs prevent colon cancer is not clear. An activ-
ity common to many NSAIDs is the ability to inhibit
prostaglandin synthesis, and there are a number of
observations consistent with this inhibition being an
w ximportant aspect of their anticancer activity 11,12 .
However, a number of studies call into question the
prostaglandin hypothesis for colorectal cancer sup-
pression by NSAIDs. For example, a sulindac
metabolite that does not inhibit prostaglandin synthe-
sis retains its ability to suppress tumor formation in
w xrats 13 . In addition, dose–response curves indicate
that sulindac-induced apoptosis requires drug concen-
trations above those required to inhibit prostaglandin
w xsynthesis 14 , and addition of exogenous prosta-
glandins to NSAID-treated cells does not spare them
w xfrom apoptosis 10 . The role of prostaglandin deple-
tion in the anti-cancer activities of NSAIDs is also
complicated by the finding that secretory phospholi-
 .pase A2 sPLA2 suppresses intestinal tumor devel-
w xopment in mice 15 : sPLA2 enhances prostaglandin
synthesis by increasing arachidonic acid release from
cellular membranes arachidonic acid is usually rate-
.limiting for prostaglandin synthesis . Cellular events
other than prostaglandin synthesis inhibition involved
in NSAID-induced apoptosis have not been thor-
oughly explored. Cell killing by NSAIDs is however
known to occur through a p53 independent pathway
w x16,17 .
As indicated above, short-chain fatty acids are
another class of molecules that can suppress colon
w xcancer 4 . These fatty acids, which include the 4-
and 5-carbon fatty acids butyrate and propionate, are
generated in the colon from the metabolism of dietary
w xfiber by bacteria in the gut 4 . Butyrate is perhaps
the most extensively studied short-chain fatty acid.
The mechanism by which butyrate prevents colon
cancer is controversial. Like NSAIDs, butyrate has
w xbeen found to arrest colon cancer cells in G1 18 ,
and induce them to undergo apoptosis in a manner
that is partially blocked by overexpression of Bcl-2
w x19 . Animal studies however, have revealed that
butyrate is an important energy molecule for colonic
epithelial cells, and its removal leads to cell death in
w xthe colon 20 . Whether butyrate serves to induce
apoptosis or fuel cell growth in vitro has been found
to depend upon the availability of alternative energy
sources, with apoptosis ensuing in when glucose is
w xavailable 21 .
We became interested in the potential role of
 .reactive oxygen species ROS in the actions of
chemopreventive agents because it is becoming in-
creasingly apparent that ROS play a central role in
the regulating cell growth and cell death. The influ-
ence of ROS on the cell appears to depend on the
species generated, their concentration, and the cellu-
lar context at the time of their production. Although
there is evidence that ROS are not essential for
apoptosis i.e., cell death occurs under conditions of
. w xhypoxia 22 , evidence has been obtained supporting
a role for ROS in apoptosis triggered by a large
w xnumber of stimuli 23 . Increased expression of glu-
tathione peroxidase has been found to suppress apop-
tosis triggered by a variety of otherwise unrelated
w xinducers 23 . In addition, oxidative damage to cellu-
lar macromolecules is a common characteristic of
w xapoptosis induced by a wide variety of stimuli 23 .
Finally, direct treatment of numerous cell types with
H O induces apoptosis. Precisely how ROS signal2 2
the cell to undergo apoptosis is not clear.
In addition to playing a role in cell death, ROS
also appear to be an essential component signals for
cell proliferation. Platelet derived growth factor in-
creases H O concentrations in vascular smooth2 2
muscle cells, and preventing the accumulation of this
 .peroxide with specific antioxidants catalase pre-
vents the activation of mitogen activated protein ki-
w xnases and DNA synthesis 24 . Apparently growth
factor-induced H O generation occurs in a context,2 2
or at levels, compatible with cell growth rather than
cell death. While H O is the active ROS for growth2 2
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factor signaling, superoxide appears to be the critical
species for mitogenic stimulation by oncogenic ras.
w xIrani et al. 25 found that fibroblasts transformed by
the ras oncogene generate considerably higher levels
of superoxide than do nontransformed cells. Squelch-
ing of this superoxide signal was found to suppress
mitogenic stimulation by oncogenic ras. The impor-
tance of superoxide for transformed cell growth is
highlighted by the finding that overexpression of
superoxide dismutase in melanoma, glioma, tongue
cancer or breast cancer cells suppresses their malig-
w xnant phenotype 26–28 . Overexpression of superox-
ide dismutase decreases the cellular superoxide levels
while increasing hydrogen peroxide, and it is not yet
clear which ROS is important for the observed phe-
notypic changes.
Given the emerging importance of ROS in the
regulation of cell growth and cell death, we decided
to examine the effect of a number of chemopreven-
tive agents on ROS generation in colorectal cancer
cells.
2. Materials and methods
2.1. Chemicals
 .Indomethacin, nordihydroguaiaretic acid NDGA ,
 .N-acetylcysteine NAC , superoxide dismutase,
 .H O , arachidonic acid sodium salt , butyric acid2 2
 . neutralized with NaOH , propionic acid neutralized
.  .with NaOH , sodium acetate, tocopherol vitamin E ,
 .isoluminol, microperoxidase MP-11 , saligenin, ben-
 .zoic acid, menadione vitamin K3 and lucigenin
 .bis-N-methylacridinium nitrate were purchased from
Sigma. SA was purchased from Fisher, dihydro-
 .dichlorofluorescein H DCF; diacetate form from2
 .Molecular Probes Eugene, OR , and 5,8,11-
eicosatriynoic acid from Biomol Plymouth Meeting,
.PA .
2.2. Cell culture
HT-29 cells were purchased from American Type
 .Culture Collection Rockville, MD and were propa-
gated on tissue culture plastic with McCoy’s 5A
medium supplemented 10% fetal bovine serum,
 .nonessential amino acids, streptomycin 50 mgrml
 .and penicillin 50 Urml . All medium components
were purchased from Life Technologies Gaithers-
.burg, MD .
2.3. H DCF oxidation assay for peroxide2
For the measurement of H DCF oxidation to fluo-2
 .rescent dichlorofluorescein DCF , cells were grown
to near confluency on a 96 well tissue culture plate,
and loaded with H DCF by adding the diacetate form2
of this compound to the medium at a final concentra-
tion of 50 mM. After 30 min, the medium was
completely removed, and 100 ml of fresh medium
was added to each well unless otherwise indicated in
.the text . After addition of test agents, DCF produc-
tion was detected with a Cytofluor microplate-read-
 .ing fluorimeter PerSerptive Biosystems with the
excitation wavelength set at 475 nm, and the emis-
sion wavelength at 525 nm. The fluorimeter was set
at a gain of 50 for these measurements. Blank wells
 .minus cells produced stable readings that generally
ranged from 70 to 90. The abscissa of the graphs
depicting the results of these assays are therefore
given a minimum value in this range.
2.4. Isoluminol assay for peroxide
For the isoluminol assay, HT-29 cells were grown
in 24 well plates and incubated with test agents for
30 min. One hundred microliter of the medium was
then removed, transferred directly into the luminome-
ter cuvette, and mixed rapidly with 186 ml of an
isoluminolrmicroperoxidase reaction mixture in a
Turner Designs luminometer using the automatic in-
jection system. The integrated counts over 30 s were
then recorded. The isoluminolrmicroperoxidase as-
say mixture was prepared as follows: 3 ml of 100
 .mM sodium borate pH 10 was mixed with 7 ml
methanol. Into this buffered methanol solution, 2 mg
of isoluminol and 0.25 mg of microperoxidase were
dissolved. This protocol was adapted from Ya-
w xmamoto et al. 29 .
2.5. Lucigenin assay for superoxide
For the superoxide assay, cells were grown on 35
mm plates with 2.5 ml of medium as described
.above . Cells were withdrawn from the incubator,
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and lucigenin was added to a final concentration of
250 mM lucigenin. When indicated, menadione was
added just prior to the lucigenin to a final concentra-
.tion of 50 mM . Photons were integrated over a 5
min period using a Turner Designs luminometer with
the 35 mm plate adapter. Test agents were added
either immediately before addition of lucigenin and
menadione, or when indicated, 10 h before the assay.
3. Results
3.1. Influence of chemopre˝enti˝e agents on cellular
peroxide le˝els
We initiated our analysis of the effects of colon
cancer chemopreventive agents on cellular ROS gen-
eration using the peroxide-sensitive probe H DCF2
w x30 . Cells are exposed to the uncharged diacetate
form of H DCF, which passes freely through the2
cellular membrane. Once inside the cells, the acetate
groups are cleaved off by nonspecific esterases, gen-
erating a charged molecule that is trapped within the
cell. In the presence of peroxides, H DCF is oxidized2
inside the cell to DCF. DCF is highly fluorescent, so
w xits production can be easily detected 30 .
Fig. 1 shows the results of H DCF oxidation2
assays measuring peroxide production in HT-29 col-
orectal carcinoma cells exposed to a number of
chemopreventive agents. Fig. 1A compares the po-
 .tency of the NSAIDs salicylic acid SA and indo-
 .methacin IND . Acetylsalicylic acid and ibuprofen
also trigger H DCF oxidation, implying that this may2
be general activity of NSAIDs Giardina, C., unpub-
.lished data . The concentrations of IND and SA
required to induce apoptosis are close to those found
to elicit a maximal ROS response 200 to 300 mM
for IND, and 4 to 8 mM for SA; Giardina, C.,
w x.unpublished data and Refs. 9,31 . In Fig. 1B, a
number of short-chain fatty acids are tested for their
ability to trigger peroxide production. Butyrate and
propionate are found to have this activity, while
acetate does not. This peroxide response mirrors the
ability of these short-chain fatty acids to induce
apoptosis in HT-29 cells: butyrate and propionate
have been found to trigger apoptosis in HT-29 cells
at concentrations were peroxide production is de-
. w xtected , while acetate does not have this activity 32 .
The results shown in Fig. 1 were derived after a
relatively short exposure period of 20 min, indicating
that the increased peroxide production may be a
direct effect of these agents. Also shown in Fig. 1B is
the H DCF oxidation induced by exposure of cells to2
exogenous H O . This result is included to demon-2 2
strate that the level of H DCF oxidation triggered by2
the NSAIDs and short-chain fatty acids is not trivial.
The ROS response triggered by the short-chain
fatty acids, IND and SA occur in a range that can be
obtained physiologically. Short-chain fatty acids are
w xpresent in the gut in the millimolar range 20 , and
plasma concentrations of 0.1 to 2 mM SA, and ;30
mM IND are obtained when they are used as anti-in-
w xflammatory drugs 33,34 .
 .We also determined whether arachidonic acid AA
can induce H DCF oxidation in colorectal cancer2
cells. Arachidonic acid is a component of cellular
membranes, and can be released through the activities
of phospholipase A2. Although the role of arachi-
donic acid and other fatty acids in the progression of
cancer is not clear, the finding that sPLA2 is a tumor
suppressor in the Min mouse model suggests that free
fatty acids such as arachidonic acid may play a role
w xin cancer prevention 15 . Arachidonic acid is also of
interest because most NSAIDs inhibit arachidonic
acid metabolism by cyclooxygenases, and therefore
serve to increase arachidonic acid levels in the cell.
As shown in Fig. 1A, arachidonic acid is able to
trigger H DCF oxidation in HT-29 cells.2
Since arachidonic acid is able to increase ROS
production, and arachidonic acid metabolism by cy-
clooxygenase is inhibited IND, we determined how
ROS generation was affected when cells were treated
simultaneously with these two agents. In the experi-
ment presented in Fig. 2, cells were treated with IND,
SA, and butyrate, either in the presence or absence of
arachidonic acid. Of all the combinations tested, a
strong synergistic response is observed only between
IND and arachidonic acid. A possible explanation for
this synergism is that IND’s inhibition of cyclooxy-
genase allows higher levels of arachidonic acid in the
cell to persist. SA is a poor cyclooxygenase inhibitor
w x34 , and the effect of BA on cyclooxygenase is not
 ..known to our knowledge . The synergism between
IND and arachidonic acid may help target the ROS-
generating activity of IND to tissues with high phos-
pholipase A2 activity. It should be noted that cancer-
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 .Fig. 1. A Arachidonic acid, salicylic acid and indomethacin increase peroxide generation in HT-29 colorectal cancer cells as determined
by the H DCF oxidation assay. Cells were loaded with H DCF as described in Section 2. Exposures to the indicated concentrations were2 2
performed for 20 min after which time H DCF oxidation to DCF was determined by measuring fluorescence. Control cultures with no2
.  .cells gave a background signal of about 100 arbitrary units , so this is the minimum value chosen for the x-axis. AA labels results from
 .arachidonic acid treated cultures, IND from indomethacin and SA from salicylic acid treated cells. B The short-chain fatty acids
propionate and butyrate increase peroxide generation, while acetate does not. The H DCF oxidation assay was performed as in Fig. 1A.2
Results are labeled as follows: BAsbutyrate, PAspropionate, and ACsacetate. H DCF oxidation by salicylic acid and by hydrogen2
 .peroxide are also shown SA and H O labeled results, respectively .2 2
Fig. 2. Indomethacin and arachidonic acid work synergistically to oxidize H DCF. H DCF oxidation was determined as in Fig. 1. DCF2 2
signal from untreated control cells is shown in lane 0. The following concentrations were used in the test lanes as indicated: AA, 100 mM
arachidonic acid; IND, 100 mM indomethacin; SA, 500 mM salicylic acid; BA, 5 mM butyrate. The solid bars are actual experimental
results. The striped bars are values derived from adding the arachidonic acid-induced increase to the increases observed from the indicated
agent. The results show the average of two independent trials.
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Fig. 3. H DCF oxidation triggered by salicylic acid, butyrate, indomethacin and arachidonic acid have a similar antioxidant sensitivity.2
 .The H DCF oxidation assay was performed as described in Fig. 1, in the absence solid black bars or presence of the following2
 .antioxidants as indicated : NAC, 25 mM N-acetylcysteine; NDGA, 25 mM nordihydroguaiaretic acid; VE, 50 mM vitamin E
 .tocopherol ; ETI, 25 mM 5,8,11-eicosatriynoic acid. The average of three assays is shown for each condition. A t-test was performed to
determine the significance of the difference observed when an anti-oxidant is present: ) indicates P values are less than 0.005 and
)) indicates values less than 0.001.
ous tissue from human colons have elevated levels
w xphospholipase A2 activity 35 .
To further characterize the H DCF oxidation re-2
sponse triggered by AA, SA, IND and butyrate, we
determined the sensitivity of this response to a num-
 .ber of chemical antioxidants Fig. 3 . All the com-
pounds under study had a similar antioxidant sensitiv-
 .ity: all were sensitive to N-acetylcysteine NAC and
 .nordihydroguaiaretic acid NDGA , but not vitamin E
 .tocopherol . Since N-acetylcysteine and NDGA are
most effective against water soluble peroxides, it
appears that the peroxides generated by these com-
pounds are primarily water soluble. Vitamin E func-
tions by breaking free radical chain reactions in
cellular membranes and is therefore usually consid-
ered a membrane antioxidant. Since vitamin E did not
affect H DCF oxidation, it is likely that peroxide2
production does not involve membrane-based free
radical reactions.
NDGA has both antioxidant and lipoxygenase in-
w xhibiting properties 36 . Lipoxygenases generate a
number of fatty acid derived peroxides in the cell, so
their inhibition by NDGA could potentially con-
tribute to the reduced rate of H DCF oxidation. To2
test this possibility, an alternative lipoxygenase in-
Fig. 4. Isoluminol chemiluminescence assay for peroxide con-
firms that salicylic acid, indomethacin, butyrate and arachidonic
acid increase peroxide generation. Cells were incubated without
 .  .any additions Control , or with 4 mM salicylic acid SA , 300
 .  .mM indomethacin IND , 8 mM butyrate BA , or 300 mM
 .arachidonic acid AA for 30 min. Medium from these cultures
were withdrawn and peroxide concentrations determined as de-
scribed in Section 2. The values shown are relative to untreated
 .cultures which are set to a value of 1 . The average of four
independent trials are shown with the bars representing the
standard deviation. P values for all treatments compared to
control are less than 0.001.
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Fig. 5. Arachidonic acid, indomethacin and salicylic acid have a
reduced H DCF oxidizing potency after a 24 h incubation with2
cells, while butyrate-induced oxidation is more stable. Cells were
 .treated with 100 mM arachidonic acid AA lanes , 100 mM
 .  .indomethacin IND lanes , 500 mM salicylic acid SA lanes or 4
 .mM butyrate BA lanes . The solid bars show H DCF oxidation2
rates after a 20 min exposure to these drugs. The gray lanes are
signals from cells incubated with the indicated agents for 24 h. In
these experiments, a portion of the medium was removed and
reapplied to cells after H DCF loading. The white bars are2
signals from cells treated with medium that had been previously
exposed to cells for 24 h.
hibitor was assessed for its ability to suppress H DCF2
 . w xoxidation: 5,8,11-eicosatriynoic acid ETI 36 . ETI
did not suppress H DCF oxidation by any of the2
compounds under study. This result indicates that
NDGA’s activity as an antioxidant is probably more
relevant to its ability to suppress H DCF oxidation2
than its lipoxygenase-inhibiting activity. ETI is in
fact reproducibly found to enhance H DCF oxidation2
 .particularly that induced by IND , as well as trigger
H DCF oxidation on its own at concentrations higher2
than those shown in Fig. 3; Giardina, C., unpublished
.data . ETI’s ability to trigger H DCF oxidation may2
be related to its ability to interfere with arachidonic
acid metabolism although this possibility has not
.been explored further .
To obtain data corroborating the H DCF oxidation2
assay for increased peroxide production in response
to IND, SA, AA and butyrate, we employed the
w xisoluminol chemiluminescence assay 29 . In this as-
say, medium was withdrawn from the cell cultures,
and tested immediately for the presence of peroxides
by rapidly mixing with isoluminol and microperoxi-
dase. In the presence of peroxides, isoluminol under-
goes a microperoxidase catalyzed reaction that gener-
ates light. This assay differs from the H DCF assay2
in a number of ways. First, extracellular rather than
intracellular peroxides are detected. Second, the iso-
luminol assay measures the level of peroxide at a
given time point, while H DCF measures how much2
peroxide has been generated over the course of a
given time period. As shown in Fig. 4, peroxide
production is found to be stimulated by SA, IND, AA
and butyrate when the isoluminol assay employed.
By comparison to H O standards, the level of per-2 2
oxide released into the medium under the conditions
shown is on the order of 10 nM.
The assays described above were performed after
 .short term exposures 20 min to an hour . We have
also detected increased peroxide production after sev-
eral hours of exposure to these agents Giardina, C.,
.unpublished data . In Fig. 5, the persistence of in-
creased H DCF oxidation after 24 h of exposure is2
assessed. Cells were treated for 24 h with AA, IND,
SA or butyrate, and then assayed for peroxide pro-
duction by the H DCF oxidation assay. In the case2
AA, SA or IND, the rate of H DCF oxidation fell2
after a 24 h exposure. The drug concentrations and
exposure times used in this experiment have a negli-
gible effect on cell viability; Giardina, C., unpub-
.lished data . It was also found that exposure of
medium containing SA, IND and AA to cells resulted
Fig. 6. Comparison of salicylate-related compounds for their
ability to induce H DCF oxidation. HT-29 cells loaded with2
H DCF were incubated with the indicated concentrations of2
 .  .  .salicylic acid SA , benzoic acid BNZ or saligenin SG for 30
min. DCF fluorescence was then measured.
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in a loss of the ability of this media to trigger
H DCF oxidation in previously untreated cells Fig.2
.5 . Inactivation of the agents required the presence of
cells, since pre-incubation in medium alone for 24 h
did not reduce their activity Giardina, C., unpub-
.lished data . This finding is consistent with the cells
metabolizing these compounds to an inactive form, or
sequestering them in some cellular compartment. In-
terestingly, butyrate-induced H DCF oxidation is re-2
producibly found to increase with a 24 h exposure
 .Fig. 5 . In addition, when medium from butyrate
treated cells is replaced with control medium, they
continue to display elevated levels of H DCF oxida-2
 .tion Giardina, C., unpublished data . Butyrate might
therefore be taken up by the cells and metabolized
more slowly than the other compounds.
 .Fig. 7. A Salicylic acid and indomethacin suppress menadione-induced superoxide generation in HT-29 cells. Lucigenin-enhanced
 .chemiluminescence of cell cultures is shown. Cells with no additions generate only low levels of chemiluminescence lane 0 , while
 . addition of 50 mM menadione increases this signal lane MD . The remaining lanes all have 50 mM MD, plus the following additions at
.  .  .  .  .the concentrations indicated in the figure : salicylic acid SA , indomethacin IND , butyrate BA , arachidonic acid AA , or superoxide
 .dismutase SOD . In these experiments, additions were made immediately prior to photon counting, with counts collected over the first 5
 .min of exposure. B The ability of salicylic acid and indomethacin to suppress menadione-induced superoxide generation is maintained
after a 10 h exposure to these drugs. Benzoic acid and saligenin have a reduced ability to suppress superoxide formation. The 0 and MD
lanes are counts from cells with no additions of plus 50 mM menadione, respectively. The remaining lanes are counts from cells exposed
to 50 mM menadione, in the presence of the following compounds: SA, 2 mM salicylic acid; IND, 200 mM indomethacin; BNZ, 2 mM
benzoic acid; SG, 2 mM saligenin. These latter agents were either added immediately prior to menadione exposure 0 h preincubation
.  .lanes or 10 h before this exposure 10 h preincubation lanes . The average of two independent trials is shown.
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A common chemical feature of the compounds
found to enhance H DCF oxidation in our studies in2
the presence of a carboxyl group although such a
group is not sufficient for such a reaction, as evi-
.denced by the lack of acetate activity; Fig. 1 . We
tested two salicylate-related compounds for their abil-
ity to trigger H DCF oxidation to determine which2
chemical groups of SA were important for peroxide
generation. Benzoic acid, which is identical to SA
except for the absence of a hydroxyl group at the
ortho position, retained some of its H DCF oxidizing2
 .activity Fig. 6 . However, an SA derivative in which
the carboxyl group is replaced by a hydroxyl
 .saligenin is inactive in this assay. This experiment
demonstrates the importance of the SA carboxyl group
for the activation of H DCF oxidation. This carboxyl2
group could be involved directly in the chemistry of
peroxide generation by SA, or serve to localize SA to
the appropriate cellular compartment.
3.2. Effects of SA, IND, AA and butyrate on superox-
ide generation
To extend our analysis of the influence of NSAIDs
and short-chain fatty acids on cellular ROS produc-
tion, we employed the lucigenin enhanced chemilu-
minescence assay to measure superoxide generation
w x25,37 . Initial experiments indicated that the NSAIDs
SA and IND may reduce basal superoxide produc-
tion, but the signals were too small to reliably assign
them to superoxide. We then turned to determining
the effect of the agents under study on superoxide
generation triggered by the vitamin K derivative,
menadione. Vitamin K-related compounds are gener-
ated by bacteria in the intestine, and their ability to
undergo redox cycling and generate superoxide has
been proposed to contribute to the development or
w xprogression of colorectal cancer 38 . As shown in
Fig. 7A, menadione increases lucigenin enhanced
chemiluminescence of HT-29 cells compare 0 to
.MD lanes . This chemiluminescence is largely elimi-
nated by addition of superoxide dismutase, indicating
that most of the menadione-activated signal is due to
superoxide production. Interestingly, both SA and
IND were found to suppress menadione-induced su-
peroxide production at concentrations similar to those
.that activate peroxide production; Fig. 7A . This
superoxide-suppressing activity was not found for
AA or butyrate. As shown in Fig. 7B, the superoxide
suppressing activities of these NSAIDs are stable and
can be observed after a 10 h incubation. The results
in Fig. 7B also indicate that benzoic acid and sali-
genin do not have this activity, indicating that both
SA hydroxyl and carboxyl groups are necessary for
full superoxide-suppressing activity.
We assessed the ability of menadione to enhance
peroxide production in HT-29 cells using the H DCF2
oxidation assay. Superoxide can be metabolized to
H O in the cell, so it was possible that menadione2 2
would increase H O levels as well as superoxide2 2
levels. As shown in Fig. 8, no increase in H DCF2
oxidation above baseline is observed when cells are
treated with menadione. It therefore appears that the
fate of superoxide in the HT-29 cells involves routes
other than conversion into peroxide. One mechanism
by which SA and IND could decrease superoxide
levels while increasing peroxide production is through
an increased rate of the superoxide dismutase reac-
tion. This model predicts that peroxide production by
SA and IND would be enhanced by menadione.
However, as shown in Fig. 8, a slight suppression in
peroxide generation by these compounds is observed,
indicating that the SA and IND are likely not increas-
ing superoxide dismutase activity.
Fig. 8. Menadione does not induce H DCF oxidation in HT-292
cells. The H DCF oxidation assay was performed as described in2
Fig. 1. Cells were exposed to the following treatments: 0, no
additions; MD, 50 mM menadione; SA, 2 mM salicylic acid;
IND, 100 mM indomethacin. Treatments were done for 30 min.
The average of two independent trials is shown.
( )C. Giardina, M.S. InanrBiochimica et Biophysica Acta 1401 1998 277–288286
4. Discussion
We have found that a number of compounds that
have demonstrated or implied chemopreventive activ-
ity for colorectal cancer profoundly affect ROS
metabolism in a colorectal cancer cell line. While all
of the agents under study AA, SA, IND and bu-
.tyrate are found to enhance peroxide production in
these cells, the two NSAIDs studied have the addi-
tional ability to suppress menadione-induced superox-
ide generation. The changes in ROS metabolism we
describe may play a role in the anti-cancer actions of
these compounds.
The importance of ROS in the transformed pheno-
type of cancer cells is emerging through the analysis
of cancer cell lines in which the balance of superox-
ide and hydrogen peroxide is altered through the
overexpression of superoxide dismutase. In cells de-
rived from a number of cancer types, including
glioma, melanoma and breast cancer, it has been
found that overexpression of superoxide dismutase
 .either Mn or CurZn superoxide dismutase sup-
w xpresses their transformed phenotype 26,28 . For ex-
ample, overexpression of Mn superoxide dismutase in
glioma cells makes cells more dependent on serum
w xfor growth and less aggressive in nude mice 26 . It
has also been observed that overexpression of CurZn
superoxide dismutase in tongue carcinoma cells de-
w xcreases their motility and invasiveness 27 . The over-
expression of superoxide dismutase in cells has two
effects: a reduction in superoxide radical and an
increase in hydrogen peroxide. It is not clear whether
one or both of these changes are important for the
observed phenotypic alterations observed upon super-
oxide dismutase overexpression. Since direct applica-
tion of hydrogen peroxide to cells can also induce
senescence, it has been proposed that increased per-
oxide load may be responsible for the growth effects
observed upon superoxide dismutase overexpression
w x28 . Consistent with peroxide playing a role in sup-
pressing carcinogenesis, it has been found that trans-
genic mouse lines that overexpress glutathione perox-
w xidase are more susceptible to skin cancer 39 .
In our studies, we noted that the two NSAIDs, SA
and IND, were also able to suppress superoxide
generation induced by menadione. Whether superox-
ide generated by other stimuli is also suppressed by
these drugs is not known. It has been found that cells
with an activated form of ras generate higher levels
of superoxide, and that the mitogenic signal gener-
ated by oncogenic ras depends on this increased
w xsuperoxide production 25 . If NSAIDs can suppress
superoxide from activated ras, this activity could
prove to be an important aspect of their anticancer
activity. Regardless of whether SA and IND suppress
superoxide from other sources, the finding that they
function to decrease superoxide generation by the
vitamin K derivative menadione could be of particu-
lar importance to the development and progression of
colon cancer. Vitamin K is synthesized in the intes-
tine by the microbial flora, and it has been proposed
that the redox cycling ability of these compounds is
at least partly responsible for the disproportionately
high rates of cancer in the lower portion of the
w xgastrointestinal tract 38 . Redox cycling by vitamin
K family members could increase mutation rates in
 . w xthe colon as discussed below 38 , or stimulate cell
proliferation by increased radical generation such as
. w xthat achieved by activated ras 25 .
A number of lines of evidence indicate that the
NSAIDs, and perhaps short-chain fatty acids like
butyrate, suppress cancer development by triggering
apoptosis of cancer cells. However, evidence consis-
tent with the NSAIDs reducing mutation rates have
also been reported. Piroxicam, for example, has been
shown to reduce azoxymethane-induced ras muta-
w xtions in rats 40 . Changes in cellular ROS production
described here may impact mutation rates. It has been
proposed that the redox cycling ability of vitamin K,
in conjunction with iron in the colon, establishes an
w xenvironment with a high mutagenic potential 38 . SA
and IND might therefore suppress superoxide-driven
free radical generation in the colon, and the resulting
DNA damage. Our finding that peroxide generation is
increased by SA, IND and butyrate, however, could
potentially lead to an increase in the mutagenic envi-
ronment. DNA damage by ROS is predicted to be
most extensive in the presence of both superoxide
and peroxide: superoxide can drive the reduction of
H O to the very damaging hydroxyl radical through2 2
w xthe Haber–Weiss reaction 41 . It is therefore possi-
ble that high superoxide levels in the colon are
driving DNA damage, and that suppressing the pro-
duction of this ROS more than compensates for the
increased peroxide production.
An alternative mechanism by which the ROS
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changes induced by the NSAIDs and short-chain fatty
acids could lower mutation rates is through maintain-
ing the expression of carcinogen detoxification sys-
tems at higher levels. A number of NSAIDs have
been shown to increase the expression of detoxifica-
tion enzymes, such as glutathione transferases, in the
w xgastrointestinal tract 7 . Many genes encoding pro-
teins involved in carcinogen detoxification are regu-
 . w xlated by the antioxidant response element ARE 42 .
The ARE, which is activated by peroxides, may be
responding to the NSAID-induced increases in perox-
ide levels.
One question that remains unresolved concerns the
 .biochemical mechanism s behind the ROS changes
observed. In this regard, it should be noted that SA
and IND have been reported to inhibit the reduction
of the arachidonic acid-derived peroxide 12-hydro-
 .peroxyeicosatetraenoic acids HPETE in platelet
w xlysates 43,44 . Although the details of this inhibition
are not known, it is generally believed that glu-
tathione peroxidase is at least partly responsible for
metabolizing this hydroperoxide. Inhibition of glu-
tathione peroxidase could account for the increased
peroxide levels observed upon SA and IND treat-
ments. Redox-cycling metals, both in the medium
and inside the cell, may contribute to the observed
ROS changes although we have found that addition
of Fe2q to the medium is ineffective at triggering
.ROS production . The inhibition of menadione-in-
duced superoxide generation by SA and IND is in-
triguing. Superoxide generation by menadione is a
multistep process, and it is not yet clear which step is
being affected. Regardless of the mechanism by which
ROS metabolism is altered, these changes could po-
tentially affect numerous cell signaling pathways.
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